Treatment of Whole Blood With Riboflavin and UV Light
| Autor: | Shirley Owusu-Ofori, Janna M. Mundt, Christine S. Olver, Jean-Pierre Allain, Joseph Kusi, Shilo Wilkinson, Alex Owusu-Ofori, Shawn D. Keil, Raymond P. Goodrich, Graham Freimanis, Caitlyn R. Martinez |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Blood transfusion Adolescent Ultraviolet Rays Blood Safety Riboflavin medicine.medical_treatment Plasmodium falciparum Cold storage Biology Critical Care and Intensive Care Medicine Polymerase Chain Reaction law.invention Hemoglobins law medicine Humans Blood Transfusion Clinical Aspects Africa South of the Sahara Polymerase chain reaction Whole blood Infectivity pathogen reduction Sub-Saharan Africa Temperature Anemia Middle Aged medicine.disease Virology Malaria Real-time polymerase chain reaction cold storage Communicable Disease Control Emergency Medicine Blood Banks Female |
| Zdroj: | Shock (Augusta, Ga.) |
| ISSN: | 1073-2322 |
| DOI: | 10.1097/shk.0000000000000280 |
| Popis: | Background: Sub-Saharan African countries utilize whole blood (WB) to treat severe anemia secondary to severe blood loss or malaria on an emergency basis. In many areas with high prevalence of transfusion-transmissible agents, blood safety measures are insufficient. Pathogen reduction technology applied to WB might considerably improve blood safety. Methods: Whole blood from 40 different donors were treated with riboflavin and UV light (pathogen reduction technology) in order to inactivate malaria parasite replication. The extent of parasite inactivation was determined using quantitative polymerase chain reaction methods and was correlated to studies evaluating the replication of malaria parasites in culture. Products were also stored for 21 days at +4°C and monitored for cell quality throughout storage. Results: Plasmodium amplicon was present in 21 samples (>100 copies/mL), doubtful in four (10–100 genome equivalents [gEq]/mL), and negative in 15 U. The majority of asymptomatic parasitemic donors carried low parasite levels, with only six donors above 5,000 copies/mL (15%). After treatment with riboflavin and UV light, these six samples demonstrated a 0.5 to 1.2 log reduction in quantitative polymerase chain reaction amplification. This correlated to equal to or greater than 6.4 log reductions in infectivity. In treated WB units, cell quality parameters remained stable; however, plasma hemoglobin increased to 0.15 g/dL. All markers behaved similarly to published data for stored, untreated WB. Conclusions: Pathogen reduction technology treatment can inactivate malaria parasites in WB while maintaining adequate blood quality during posttreatment cold storage for 21 days. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|